Skip Navigation LinksHome > January 28, 2005 - Volume 19 - Issue 2 > Atazanavir plus ritonavir or saquinavir, and lopinavir/riton...
Clinical Science

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

Johnson, Margaret; Grinsztejn, Beatriz; Rodriguez, Claudia; Coco, Jeffrey; DeJesus, Edwin; Lazzarin, Adriano; Lichtenstein, Kenneth; Rightmire, Anna; Sankoh, Serap; Wilber, Richard

Free Access

This paper has been removed from this issue because of typographical errors. The article was published in Volume 19(7), cover date 29 April 2005, pp. 685-694.

Cited By:

This article has been cited 20 time(s).

AIDS Research and Human Retroviruses
Incidence of Hyperbilirubinemia and Jaundice Due to Atazanavir in a Cohort of Hispanic Patients
Bissio, E; Lopardo, GD
AIDS Research and Human Retroviruses, 29(3): 415-417.
AIDS Research and Human Retroviruses
Short Communication Fasting Increases Serum Concentrations of Bilirubin in Patients Receiving Atazanavir: Results from a Pilot Study
Lopardo, G; Bissio, E; Espinola, L; Gallego, P; Stambullian, M; Gadano, A
AIDS Research and Human Retroviruses, 29(3): 456-460.
Janac-Journal of the Association of Nurses in AIDS Care
Current clinical issues impacting the lives of patients living with HIV/AIDS
Gallagher, DM
Janac-Journal of the Association of Nurses in AIDS Care, 18(1): S11-S16.
International Journal of Std & AIDS
Practical discussion on switching studies and how this relates to managing lipids - Discussion
Johnson, M; Wilkins, E; Moyle, G; Churchill, D; Johnson, M; Collins, S; Baily, G; Nair, D; Gazzard, B; Alcorn, K; Hanekom, W
International Journal of Std & AIDS, 16(): 27-30.

Journal of Hepatology
Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management
Nunez, M
Journal of Hepatology, 44(): S132-S139.
Journal of Infectious Diseases
The survival benefits of AIDS treatment in the United States
Walensky, RP; Paltiel, AD; Losina, E; Mercincavage, LM; Schackman, BR; Sax, PE; Weinstein, MC; Freedberg, KA
Journal of Infectious Diseases, 194(1): 11-19.

Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes
Jones, SP; Waitt, C; Sutton, R; Back, DJ; Pirmohamed, M
AIDS, 22(): 1293-1298.

Antiviral Therapy
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
Piketty, C; Gerard, L; Chazollon, C; Marcelin, AG; Clavel, FO; Taburet, AM; Calvez, V; Madelaine-Chambrin, I; Molina, JM; Aboulker, JP; Girard, PM
Antiviral Therapy, 11(2): 213-221.

Expert Opinion on Drug Metabolism & Toxicology
Clinical pharmacology, efficacy and safety of atazanavir: a review
Bentue-Ferrer, D; Arvieux, C; Tribut, O; Ruffault, A; Bellissant, E
Expert Opinion on Drug Metabolism & Toxicology, 5(): 1455-1468.
New Microbiologica
Evaluation of atazanavir C-trough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir
Gianotti, N; Seminari, E; Guffanti, M; Boeri, E; Villani, P; Regazzi, M; Bigoloni, A; Schira, G; Tiberi, S; Fusetti, G; Lazzarin, A; Castagna, A
New Microbiologica, 28(2): 119-125.

Expert Opinion on Pharmacotherapy
Treatment of dyslipidaemia in HIV-infected persons
Manuel, O; Thiebaut, R; Darioli, R; Tarr, PE
Expert Opinion on Pharmacotherapy, 6(): 1619-1645.
HIV Medicine
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
Gazzard, BG
HIV Medicine, 9(8): 563-608.
HIV Medicine
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)
Gazzard, B
HIV Medicine, 6(): 1-61.

Efficacy and safety of once-daily regimens in the treatment of HIV infection
Molina, JM
Drugs, 68(5): 567-578.

Circulation-Cardiovascular Genetics
Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals A Longitudinal Study
Rotger, M; Bayard, C; Taffe, P; Martinez, R; Cavassini, M; Bernasconi, E; Battegay, M; Hirschel, B; Furrer, H; Witteck, A; Weber, R; Ledergerber, B; Telenti, A; Tarr, PE
Circulation-Cardiovascular Genetics, 2(6): 621-U246.
Lancet Oncology
Comparative pharmacogenomics of antiretroviral and cytotoxic treatments
Stebbing, J; Bower, M
Lancet Oncology, 7(1): 61-68.

HIV Clinical Trials
Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily anti retroviral-experienced HIV-infected patients
de Mendoza, C; Valer, L; Ribera, E; Barreiro, P; Martin-Carbonero, L; Ramirez, G; Soriano, V
HIV Clinical Trials, 7(4): 163-171.
Antiretroviral drugs and liver injury
Soriano, V; Puoti, M; Garcia-Gascó, P; Rockstroh, JK; Benhamou, Y; Barreiro, P; McGovern, B
AIDS, 22(1): 1-13.
PDF (257) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Rescue Therapy With Once-Daily Atazanavir-Based Regimens for Antiretroviral-Experienced HIV-Infected Patients
Dronda, F; Antela, A; Pérez-Elías, MJ; Casado, JL; Moreno, A; Moreno, S
JAIDS Journal of Acquired Immune Deficiency Syndromes, 42(2): 258-259.
PDF (184) | CrossRef
Pharmacogenetics and Genomics
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy
Arnedo, M; Taffé, P; Sahli, R; Furrer, H; Hirschel, B; Elzi, L; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Bergmann, S; Beckmann, JS; Telenti, A; Tarr, PE; the Swiss HIV Cohort Study,
Pharmacogenetics and Genomics, 17(9): 755-764.
PDF (145) | CrossRef
Back to Top | Article Outline

© 2005 Lippincott Williams & Wilkins, Inc.


Article Level Metrics